admin

Partnership combines miRecule’s unique RNA therapeutic discovery and conjugation platforms with Sanofi’s NANOBODY® technology to create a groundbreaking treatment for FSHD miRecule will receive an upfront payment with potential future milestone payments of nearly $400 million, in addition to tiered royalties Collaboration marks the first licensing transaction leveraging miRecule’s proprietary DREAmiR™ discovery platform, validating foundational science, and bolstering commitment to further expansion of the company’s RNA therapeutic pipeline October 04, 2022 07:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–miRecule, Inc., an innovator of next-generation RNA therapeutics, today announced a strategic collaboration and exclusive license agreement with Sanofi to develop and commercialize a best-in-class antibody-RNA conjugate (ARC) for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The collaboration marks miRecule’s first licensing transaction leveraging its proprietary DREAmiR platform.

October 04, 2022 08:29 AM Eastern Daylight Time

GAITHERSBURG, Md–(BUSINESS WIRE)–Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced that the Defense Health Agency (DHA) has awarded an additional $5 million to support clinical development of APT’s adaptive bacteriophage (“phage”) therapy in treatment of diabetic foot osteomyelitis (DFO). APT is evaluating safety and efficacy of its precision phage-based therapy in the ongoing Phase 1/2 DANCE™ (DFO Adaptive Novel Care Evaluation) clinical trial.

Johns Hopkins University is teaming with two D.C.-area institutions, Howard University and the National Institutes of Health, to create a new accelerator to help companies and research scientists focused on treating neurological conditions.

The nonprofit biotechnology accelerator, NeuroTech Harbor, is funded by an NIH investment of $5 million a year over five years, which could go up to $20 million annually. The NeuroTech Harbor plans to launch 45 new neurological companies over the next five years.

Image: NeuroTech Harbor Executive Director Sri Sarma views the project as a catalyst to turn Baltimore into a the Silicon Valley of neurological technology. COURTESY OF SRI SARMA

The BioHealth Capital Region has made a name for itself in the last few years, currently holding tight to its #4 ranking on the Genetic & Engineering News (GEN) Top 10 Biopharma Clusters list. As more life science companies flock to the region, though, a new challenge arises – how do we create a strong pipeline of local talent to support their needs? This pipeline not only includes the high concentration of experienced talent the BHCR is known for but entry-level employees and people without four-year degrees who can be trained on-the-job.

Did you miss the 8^th Annual BioHealth Capital Region Forum? Below we are sharing many of the panels, fireside chats, and keynotes from this event hosted on September 20^th, 2022, from USP in Rockville, Maryland.

The year’s theme was “Imagine the Future Together,” with discussions on Healthcare Innovation, Change, Diversity, Equity, and Inclusion.

Thank you to all the Sponsors and Partners of the event and region this year.

Quantum World Congress is where global trailblazers, game-changers, innovators, and visionaries come together to accelerate a quantum-ready future

Quantum World Congress is the first-of-its-kind global conference, exposition, and networking event that brings a quantum-ready future into focus. Cross-sector, multi-disciplinary leaders and participants from around the world will gather for three days—November 29-December 1—in Washington, D.C. at the Ronald Reagan Building and International Trade Center to explore this groundbreaking field. This event welcomes quantum technology visionaries, policymakers, researchers, business and investment leaders, educators, and students to discuss and showcase major developments in quantum solutions, research, education, workforce, thought leadership, policy, business, and investment. Technology builders and buyers will also discuss national and global progress as well as challenges and opportunities in the development of quantum computing, sensing, communications, and materials.

We are pleased to share an exciting new funding opportunity from the NIH Blueprint Innovation Hubs that you or your colleagues may be interested in.

NeuroTech Harbor and CIMIT’s CINTA program, through the NIH Blueprint MedTech Incubator hubs program, are currently seeking proposals from academic and industry applicants who have emerging technologies that aim to improve the diagnosis and/or treatment of disorders of the nervous system. Awards up to $500K per year (up to 4 years) to the most promising and innovative neurotechnologies to help support their development journey toward commercialization.

#KeiretsuBacked Sisu Global named in the list of the 100 Most Influential Medtech Companies! They were awarded in the latest issue of Medical Design & Outsourcing, read here: https://bit.ly/3LRI0EI

NEWARK, Del., Sept. 29, 2022 /PRNewswire/ — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announces a Biomanufacturing Readiness Levels (BRLs) framework to lay the groundwork for a universal assessment of technology maturity and readiness level for commercial biomanufacturing technology adoption.

The BRL framework, described in the Biotechnology and Bioengineering journal, will benefit technology innovators, developers, and adopters with the ability to assess the maturity level of technology implementation during the clinical trials and commercial scale manufacturing processes that will allow them to overcome technology adoption hurdles from inception to commercialization. Modeled after the successful Manufacturing Readiness Levels developed by the Department of Defense, BRLs provide a tailored approach to the technology adoption journey that is specific to the biopharmaceutical industry.